These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 16442096)

  • 1. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
    Harada D; Tsukumo Y; Takashima Y; Manabe H
    Eur J Pharmacol; 2006 Feb; 532(1-2):128-37. PubMed ID: 16442096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
    Harada D; Takada C; Nosaka Y; Takashima Y; Kobayashi K; Takaba K; Manabe H
    Int Immunopharmacol; 2009 Jan; 9(1):55-62. PubMed ID: 18854230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyses of a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
    Harada D; Takada C; Tsukumo Y; Takaba K; Manabe H
    J Dermatol Sci; 2005 Mar; 37(3):159-67. PubMed ID: 15734285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models.
    Yamamoto S; Sugahara S; Ikeda K; Shimizu Y
    Eur J Pharmacol; 2006 Nov; 550(1-3):166-72. PubMed ID: 17010967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059.
    Yamamoto S; Sugahara S; Ikeda K; Shimizu Y
    Eur J Pharmacol; 2007 Mar; 559(2-3):219-26. PubMed ID: 17250824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rolipram, a phosphodiesterase IV inhibitor, on allergic footpad swelling using various adjuvants in mice.
    Yamaki K; Alam AH; Hossain MA; Taneda S; Yanagisawa R; Takano H; Yoshino S
    Scand J Immunol; 2005 Oct; 62(4):378-84. PubMed ID: 16253125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
    Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis.
    Videla S; Vilaseca J; Medina C; Mourelle M; Guarner F; Salas A; Malagelada JR
    J Pharmacol Exp Ther; 2006 Feb; 316(2):940-5. PubMed ID: 16254133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
    Souza DG; Cassali GD; Poole S; Teixeira MM
    Br J Pharmacol; 2001 Nov; 134(5):985-94. PubMed ID: 11682446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury.
    Tang HF; Lu JJ; Tang JF; Zheng X; Liang YQ; Wang XF; Wang YJ; Mao LG; Chen JQ
    Int Immunopharmacol; 2010 Apr; 10(4):406-11. PubMed ID: 20074667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice.
    Yamaki K; Li X; Hossain MA; Alam AH; Taneda S; Yanagisawa R; Takano H; Yoshino S
    Immunol Invest; 2007; 36(2):131-45. PubMed ID: 17365015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
    Harada D; Ikeda Y; Nosaka Y; Kobayashi K; Manabe H
    J Dermatol Sci; 2008 Sep; 51(3):215-9. PubMed ID: 18539440
    [No Abstract]   [Full Text] [Related]  

  • 13. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
    Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
    J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of an atopic dermatitis-like skin model in a hairless mouse by repeated elicitation of contact hypersensitivity that enables to conduct functional analyses of the stratum corneum with various non-invasive biophysical instruments.
    Matsumoto K; Mizukoshi K; Oyobikawa M; Ohshima H; Tagami H
    Skin Res Technol; 2004 May; 10(2):122-9. PubMed ID: 15059180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.
    Bäumer W; Gorr G; Hoppmann J; Ehinger AM; Rundfeldt C; Kietzmann M
    J Pharm Pharmacol; 2003 Aug; 55(8):1107-14. PubMed ID: 12956900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice.
    Thompson BE; Sachs BD; Kantak KM; Cherry JA
    Eur J Neurosci; 2004 May; 19(9):2561-8. PubMed ID: 15128409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
    Yamamoto S; Sugahara S; Naito R; Ichikawa A; Ikeda K; Yamada T; Shimizu Y
    Eur J Pharmacol; 2006 Jul; 541(1-2):106-14. PubMed ID: 16780833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice.
    Yamaki K; Li X; Uchida H; Alam AH; Hossain MA; Yanagisawa R; Takano H; Taneda S; Hayashi H; Mori Y; Yoshino S
    J Pharm Pharmacol; 2004 Jul; 56(7):877-82. PubMed ID: 15233866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.
    Aoki M; Fukunaga M; Sugimoto T; Hirano Y; Kobayashi M; Honda K; Yamada T
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1142-9. PubMed ID: 11504812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.